Xeljanz® (tofacitinib), Xeljanz XR (tofacitinib) – New indication
On December 14, 2021, Pfizer announced the FDA approval of Xeljanz/Xeljanz XR (tofacitinib), for the treatment of adult patients with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
Top